Highlights d The crystal structure of PCPE-1 bound to the C-propeptides has been determined d The N terminus of one propeptide chain binds to the CUB1CUB2 fragment of PCPE-1 d PCPE-1 seems to unravel the propeptide trimer to enable proteolytic release d Molecular modeling with the proteinase and its substrate supports this hypothesis
In Brief
Collagens are the most abundant proteins in mammals. Fiber-forming collagens are synthesized as procollagens, where the C-propeptides are released by specific proteinases (BMP-1). C-propeptide release is accelerated by another extracellular matrix protein called PCPE-1. Here, based on structural data, the authors present a mechanism for the acceleration of C-propeptide release.
INTRODUCTION
Fibrosis, an important pathogenic factor in diseases affecting most organs (notably heart, liver, and lung), contributes to up to 45% of deaths in the developed world (Rockey et al., 2015; Mehal et al., 2011) . It is characterized by excessive accumulation of extracellular matrix (ECM), in response to injury, infection, and inflammation, mainly in the form of collagen fibers. Despite the importance of fibrosis, currently there are no approved antifibrotic therapies. One approach is to control the deposition of collagen fibers by targeting their biosynthetic pathway. Among the 28 different genetic types of collagen in humans (RicardBlum, 2011) , the so-called fibrillar collagens (types I, II, III, V, and XI) are synthesized in precursor form, procollagens ($450 kDa), where the central triple-helical region is flanked by trimeric N-and C-terminal globular propeptides ($50 kDa and $90 kDa, respectively). These are removed by specific proteinases, usually the bone morphogenetic protein-1 (BMP-1)/tolloid-like metalloproteinases (BTPs) for the C-propeptides (Vadon-Le Goff et al., 2015) . The BTPs consist of an N-terminal astacin-like catalytic domain followed by several CUB (complement C1r/C1s, Uegf, Bmp-1) and EGF (epidermal growth factor) domains. which are important for substrate specificity (Wermter et al., 2007; Berry et al., 2009 ). The rate-limiting step in the assembly of mature collagen molecules into fibrils is the release of the C-propeptides (Kadler et al., 1987) . In addition to fibrillar procollagens, BTPs act on other ECM substrates as well as growth factor precursors or antagonists, raising the possibility of off-target effects when using BTP inhibitors to control C-propeptide cleavage (Vadon-Le Goff et al., 2015) .
Some time ago Adar et al. (1986) described an ECM protein that accelerates the release of the C-propeptides from procollagen I by BMP-1 by up to 20-fold, called procollagen C-proteinase enhancer-1 (PCPE-1). This protein ($55 kDa) consists of two CUB domains and a C-terminal NTR domain, where the intact CUB1CUB2 region (henceforth C1C2) is both necessary and sufficient for enhancing activity (Kronenberg et al., 2009) . Previous studies have revealed that the role of PCPE-1 is specific for release of the C-propeptides from fibrillar procollagens, having no effect on BMP-1 activity for a range of other substrates (Moali et al., 2005; Petropoulou et al., 2005) . This observation raised the possibility that PCPE-1 might be an attractive target for controlling BTP activity and hence the deposition of collagen fibrils in the ECM.
Early observations showed that maximum enhancing activity occurs when the amounts of PCPE-1 and procollagen are approximately equivalent, suggesting that PCPE-1 forms a complex with the substrate (Moschcovich et al., 2001 ). This was later confirmed and the binding site localized to the C-propeptide region, with a dissociation constant in the nanomolar range (Vadon-Le Goff et al., 2011) . Further studies by small-angle X-ray scattering (SAXS) revealed that C1C2 binds to the stalk/base region of the free C-propeptide trimer, which has the shape of a flower (Bourhis et al., 2012a; Sharma et al., 2017) , close to the site where it is cleaved from the rest of the procollagen molecule by BTPs (Bourhis et al., 2013) . Also, kinetic studies have shown that saturating concentrations of PCPE-1, or C1C2, increase the catalytic efficiency (k cat /K M ) of BMP-1 by over 10-fold, due to a small reduction in K M and a $ 4-fold increase in k cat , using either procollagen I (Moschcovich and Kessler, 2016) or a shortened form of procollagen III (Bourhis et al., 2013) . Despite these results, two questions remain. Why is the binding stoichiometry one molecule of PCPE-1 (or C1C2) to one C-propeptide trimer? And more generally, what is the molecular mechanism by which PCPE-1 binding enhances the activity of BTPs? Here we present the crystal structures of two forms of a complex between the active C1C2 region of PCPE-1 and the C-propeptide trimer of procollagen III. Together with site-directed mutagenesis, enzyme assays, binding studies, and molecular modeling, these results not only account for the observed stoichiometry but also provide a plausible mechanism for enhancement through localized unraveling of the procollagen trimer.
RESULTS
Two forms of the complex were crystallized using the active C1C2 fragment of human PCPE-1 (Bourhis et al., 2013) . For the first, C1C2 was complexed with the C-propeptide trimer of procollagen III (CPIII-His) where each chain consists of an N-terminal His tag followed by the entire sequence of the C-propeptide (245 residues) starting at Asp1 at the P1 0 position of the BMP-1 cleavage site ( Figure 1A ). For the second we used CPIII-Long, which includes a 37-residue insert between the His tag and the C-propeptide of CPIII-His ( Figure 1A ). This insert consists of the last three Gly-X-Y triplets of the triple helix and the entire C-telopeptide sequence N-terminal to the BMP-1 cleavage site (Bourhis et al., 2013) . For both CPIII-His and CPIIILong, residue numbering begins at Asp1 ( Figure 1A ) with negative numbers used for more N-terminal residues. Crystal structures were determined to resolutions of 2.70 Å and 2.78 Å , respectively (Table 1 ). In the structure of CPIII-His:C1C2, C1C2 is complete for residues 8-250 (numbered from the N-terminal residue following removal of the signal peptide) except for residues 126-132 corresponding to the inter-domain linker. Each chain of CPIII-His is complete to the C terminus (residue 245) from residue 5 (chain A), 7 (chain B), or 9 (chain C) with the exception of four residues (98-101) in a surface loop in chain C. The CPIII-Long:C1C2 structure is isomorphous with the CPIIIHis:C1C2 structure, but nearly half of CUB2 could not be modeled due to disorder (missing residues: 133-144, 164-175, 195-208, 217-227) . Also, no electron density was visible for CPIII-Long for the extended region N-terminal to residues 5 (chain A), 9 (chain B), and 10 (chain C). As otherwise the two crystal structures are very similar (root-mean-square deviation [RMSD] 0.49 Å for 882 Ca atoms), the following description and figures are based on the more complete CPIII-His:C1C2 structure.
Structure of the Complex
A side view of the CPIII:C1C2 complex ( Figure 1B) shows the characteristic stalk, base, and petal regions of the CPIII trimer (Bourhis et al., 2012a) as well as C1C2, which is bound mostly to the stalk region, as previously suggested from low-resolution SAXS data (Bourhis et al., 2013) . Importantly, when viewed down the axis of the CPIII trimer ( Figure 1C ), the high-resolution structure extends these previous observations to show that C1C2 binds to chains A and B of CPIII, with no binding to chain C. As shown by footprint mapping, the interactions of CUB1 and CUB2 with CPIII span the full length of the stalk region ( Figure S1A ).
Close-up views of the complex (Figures 2A and 2B) reveal more details of the interactions. Lys35 in the base region of chain A (CPIII) forms salt bridges with Glu60 and Asp109 in CUB1. These acidic residues are also involved in coordination of a Ca 2+ ion in CUB1 (see also Figure S2 ). In addition, Lys18 in chain B (CPIII) forms salt bridges with Glu183 and Asp233 in CUB2, which again are involved in Ca 2+ coordination. Interactions involving Lys18 and Lys35 with Ca 2+ binding sites in C1C2 were previously predicted based on site-directed mutagenesis Bourhis et al., 2013) , although it was not known at the time that these involved two different chains of CPIII. In addition to Lys18 and Lys35, the structure reveals hitherto unknown roles for the highly conserved residues Glu12 and Glu25 in stabilizing the complex with C1C2. Thus, Glu12 in chain A (CPIII) forms a salt bridge with Arg91 (CUB1; Figure 2C ), while Glu25 in chain B (CPIII) forms a salt bridge with Arg189 (CUB2; Figure 2B ). Furthermore, the highly conserved Tyr67 in CUB1 and its equivalent in CUB2, Tyr190 (see sequence alignment in Blanc et al., 2007) , stabilize Lys35 in chain A and Lys18 in chain B of CPIII, respectively, via hydrophobic interactions with their hydrocarbon chains (Figures 2A, 2B, and S2) .
Except for the first few residues in chain A (see below), all of the C1C2 interacting residues in chain A of CPIII bind solely to CUB1. In addition to Glu12 and Lys35 involved in salt bridges, these comprise Ser16 and Ser19/Gln23 which form van der Waals and hydrophobic interactions with Thr89/Phe90 and Leu61, respectively, of CUB1. Phe90 (CUB1) was previously shown to be essential for PCPE-1-enhancing activity . As well as its interactions with chain A, Phe90 interacts with chain B via Met14, Leu17, and Lys18 ( Figure 2B ), thus forming a hydrophobic core in the center of the CPIII:C1C2 complex. Apart from Phe90 (CUB1), chain B interacts mainly with CUB2, including Lys18 and Glu25 involved in salt bridges, an H bond between Asp11 and Val236 (CUB2), Met14 and Thr15 interfacing with Ser235 and Val236 (CUB2), and His48 with Tyr187 (CUB2). Finally, Asn21 (chain B) interfaces with Leu61 (CUB1) and Tyr187/Arg189 (CUB2), and Glu25 (chain B) interfaces with Pro63 (CUB1). Altogether, the total buried surface area between C1C2 and CPIII is 1,935 Å 2 , made up of 838 Å 2 between chain A and CUB1, 257 Å 2 between chain A and CUB2, 316 Å 2 between chain B and CUB1, and 524 Å 2 between chain B and CUB2. In addition to the interactions between CPIII and C1C2, there are interactions between CUB1 and CUB2, accounting for a total buried surface area of 794 Å 2 . In CUB1, these involve residues projecting from one edge of the jelly-roll structure in the region of Pro63, Gln81, Phe90, and Ala93. These interact with residues projecting from one face of CUB2 in the region of Tyr187/ Arg189, Asp202/Asp203, Tyr190, and Leu234, respectively (Figure S1B) . With the exception of Gln81 (CUB1) which forms an H bond with Asp203 (CUB2), all these contacts are van der Waals or hydrophobic interactions. This edge-face interaction is also characterized by an approximately 45 rotation between the long axes of the two CUB domains ( Figure 1D ). When compared with the relatively elongated low-resolution structure of fulllength PCPE-1 in solution (Bernocco et al., 2003; Kronenberg et al., 2009) , the ability of CUB1 and CUB2 to interact in this way in the complex confirms that there is considerable flexibility in the inter-domain linker.
Toward the Mechanism of Action of PCPE-1 A particularly interesting finding was the interaction between the N-terminal residues of CPIII chain A with C1C2. For chains B and C, the visible N-terminal regions begin at Lys7 and Asn9, respectively, and do not interact with C1C2. In contrast, the visible N-terminal region of chain A begins with residue Asp5 and appears to be ''pulled'' toward C1C2 (Figure 1D ), where it is accommodated in the cleft between its two CUB domains (Figure 2C) . In particular, Asp5 (chain A) forms a salt bridge with Arg55 (CUB1) and its carbonyl oxygen forms a hydrogen bond with Arg91 (CUB1), which itself forms a salt bridge with Glu12 (chain A). In addition, Phe6 (chain A) is buried in an apolar trench involving Pro94, Pro157, Ile159, and Leu234 in C1C2 (Figure S3 ), where Leu234 also makes hydrophobic contacts with Ile8 (chain A) ( Figure 2C ). Similar observations were made with the CPIII-Long:C1C2 structure.
These interactions involving the N-terminal sequence of CPIII suggest a possible molecular mechanism by which PCPE-1 enhances the release of the C-propeptides from fibrillar procollagens. Binding of C1C2 to one of the three chains of the C-propeptide trimer might unravel the procollagen molecule in the region of the proteolytic cleavage site. Since the active site of the BTPs is too small to accommodate all three procollagen chains , this would isolate chain A allowing it to enter the active site, thus accelerating the action of BTPs. To test this hypothesis, we carried out site-directed mutagenesis of residues in C1C2 that interact with the ''pulled'' N terminus of chain A (CPIII), followed by enzyme assays and surface plasmon resonance (SPR) to measure their effects on enhancing activity and substrate binding. For these experiments we used mini-procollagen III as a substrate, which is similar to CPIII-Long but includes a much longer region of the C-terminal triple-helical region (Moali et al., 2005) .
The effects of the following C1C2 mutations were studied (Figure 3A) : Arg91Ala, Leu234Glu, Arg55Ala, Arg55Ala/Leu234Glu, and Arg55Ala/Arg91Ala/Leu234Glu. Neither Arg55Ala nor Arg91Ala affected enhancing activity ( Figure 3B ) relative to wild-type C1C2. For Leu234Glu there was a decrease of 15% and with the double mutant (Arg55Ala/Leu234Glu) the decrease was 30%. With the triple mutant (Arg55Ala/Arg91Ala/Leu234-Glu), enhancing activity fell by 75%.
Previous studies have shown that the enhancing activity of PCPE-1 follows closely its affinity for procollagen. For example, alanine mutations at Lys18 or Lys35 in CPIII, or at Asp68 or Asp191 in PCPE-1, were sufficient to raise dissociation constants beyond measurable levels Bourhis et al., 2013) . We therefore used SPR to measure the binding affinities of the C1C2 mutants presented here. As shown in Figures 3C  and 3D , mutations Arg91Ala and Leu234Glu increased dissociation constants about 50-and 20-fold, respectively. In contrast, little change in affinity was seen with the Arg55Ala mutation. For the double mutant (Arg55Ala/Leu234Glu), again there was an approximately 50-fold increase in dissociation constant (K D ), while for the triple mutation (Arg55Ala/Arg91Ala/Leu234Glu) the increase was over 100-fold. In all cases, however, dissociation constants could be measured, showing the effects of these mutations to be subtler than those investigated in the past (see Figure S4 . Finally, to test whether the ''pulled'' chain might be accessible to cleavage by BTPs, we modeled the interaction of the BMP-1 catalytic domain with the procollagen:C1C2 complex ( Figure S5 ). To do so, since there is limited structural information available on the C-telopeptide region that connects the C-propeptide to the triple-helical region of the procollagen molecule (Jones and Miller, 1987; Liu et al., 1993; Malone and Veis, 2004) , we clamped this region at each end using the CPIII:C1C2 structures reported here and that of the C-terminal region of collagen III (Boudko et al., 2008) . For BMP-1, we used the crystal structure of the catalytic domain , which packed close to C1C2 in the complex, burying an additional surface area of 785 Å 2 . In this way it was possible to extend the N-terminal region of chain A into the active-site cleft of BMP-1 (Figure 4) with Asp1 bound to Arg176 in the S1 0 pocket and the scissile bond positioned for nucleophilic attack by a zinc-bound water molecule polarized by the essential Glu93. It also placed two tyrosine residues on the N-terminal side of the cleavage site close to the vicinal disulfides, in accordance with the putative role of the latter in hydrophobic interactions (Richardson et al., 2017) .
DISCUSSION
We report here the high-resolution structures of the CUB domains of PCPE-1. Both domains share the same structural features as the subset of Ca , 2015) . These features include the two 4-stranded b sheets, three conserved acidic residues, and a tyrosine residue involved in Ca 2+ coordination. In addition, we found that Tyr67 and Tyr190 stabilize the interactions involving Lys35 (chain A) and Lys18 (chain B), respectively. These stabilizing tyrosines are also conserved in the CUB domains of neuropilins, complement proteases, and BTPs, but not those of cubilin ( Figure S2 ) or TSG-6. We also compared the structure of CPIII in the complex with that of CPIII alone (Bourhis et al., 2012a) . For the trimer, an RMSD value of 1.25 Å (669 a carbons) was obtained. When comparing individual chains, however, the RMSD for chain A (0.91 Å ) was higher than for chains B and C (0.63 Å and 0.68 Å , respectively). Close inspection shows a distortion of chain A on complex formation, in the base and stalk regions, as well as changes in the relative orientations of the chains. We also note that the asymmetry previously reported for CPIII alone, where one end of helix 4 in one of the three chains is distorted, is unchanged when bound to C1C2. The residues involved are Leu138 and Leu139. In addition, the same chain has altered side-chain conformations for Arg39, Arg42, and Phe46, with or without C1C2 bound. All these residues are involved in chainchain interactions, and the asymmetry is found in chain A. This feature might specifically direct C1C2 binding to the AB face of CPIII.
The structures reported here, where one molecule of C1C2 binds to chains A and B of the CPIII trimer, immediately explain why maximum enhancing activity requires a 1:1 molar ratio of interactants. With only chain C available, binding of additional molecules of C1C2 is impossible. Concerning binding affinity, previous studies have shown that decreases in PCPE-1 enhancing activity, following mutations in Lys18 and Lys35 and their binding partners in C1C2, are mirrored by increased dissociation constants Bourhis et al., 2013 ). This was not always the case in the results reported here. As See also Figure S4 .
expected, the Arg55Ala mutation in C1C2 had no effect on enhancing activity and there was no significant increase in dissociation constant. In contrast, the Arg91Ala mutation had no effect on enhancing activity despite a 50-fold increase in dissociation constant, while a similar increase in K D was accompanied by a detectable reduction in enhancing activity for the double mutant Arg55Ala/Leu234Glu. To explain these observations, we propose that enhancing activity requires tight binding of C1C2 to the stalk/base region of CPIII and additional binding to the N-terminal region in order to isolate chain A. Both these interactions contribute to overall affinity. For the same increase in K D , mutations in C1C2 affecting interactions with the stalk region of CPIII (such as Arg91Ala) will have less effect on enhancing activity than mutations affecting interactions with the N-terminal region (such as Arg55Ala/Leu234Glu). In the CPIII-Long:C1C2 structure, no electron density was visible for CPIII-Long in the region encompassing the BMP-1 cleavage site, the C-telopeptide, the cystine knot and the short triple helix and the N-terminal His tag ( Figures 1A and S5 ). Yet the interactions involving the N-terminal residues Asp5 to Ile8 in chain A were identical to those in the CPIII-His:C1C2 structure. This shows that the presence of the N-terminal His tag in CPIIIHis did not change the interactions of chain A with C1C2. It also shows that the C-telopeptide region is mostly unstructured, Beginning with the structure of the CPIII-His:C1C2 complex, modeling extends chains A, B, and C of CPIII toward the C-telopeptide region. Chain A enters the active site of the BMP-1 catalytic domain where the P1 0 residue, Asp1, interacts with Arg176 in the S1 0 pocket, in close proximity to the essential Glu93 and the catalytic water molecule bound to the active-site zinc. Also shown are Cys64 and Cys65, which form a vicinal disulfide bond in the region of Tyr-2 and Tyr-3 in chain A. The negative sign indicates residues on the non-prime side of the cleavage site. See also Figure S5 .
as previously suggested by modeling and nuclear magnetic resonance studies (Jones and Miller, 1987; Liu et al., 1993; Malone and Veis, 2004) . There is just one modeling study of the C-telopeptides when all three chains are anchored at each end by the C-propeptides and the collagen triple helix (Malone et al., 2005) , and this was for procollagen I. A feature of this region is the transition from the collagen triple helix, in which the three chains are staggered axially by 2.86 Å , to the coiled-coil region in the C-propeptides, where all three chains are in register (Beck and Brodsky, 1998) . This inevitably leads to a looser structure for the more C-terminal so-called trailing strand in the triple helix, which corresponds to the looped chain A in the model (Figure 4) . It also led to kinks in chains B and C in the crosslinking region in the model that are not present in chain A ( Figure S5 ). The model was built assuming that BMP-1 cleaves the chain that is ''pulled'' into the C1C2 interface. An alternative possibility is that once chain A has been teased out by C1C2, chains B or C would become more available for proteolysis. Energetically, however, the model shown here is preferred, given that this also includes interactions between C1C2 and BMP-1, which would help direct the enzyme to chain A. This is consistent with the observed increased binding of an inactive form of BMP-1 to mini-procollagen III when this substrate is pre-bound with C1C2 (Bourhis et al., 2013) , albeit that the binding of C1C2 to BMP-1 alone is weak (Bekhouche et al., 2010) , suggesting cooperativity in binding of BMP-1 to both C1C2 and CPIII. Presumably once the first chain has been cleaved, chains B and C should become more exposed and therefore more susceptible to proteolysis, perhaps involving redocking of PCPE-1 to the propeptide regions of these chains. This system is similar to the cleavage of collagen molecules by matrix metalloproteinases (MMPs), where again the active site of the protease is too small to accommodate all three chains of the substrate (Bertini et al., 2012; Manka et al., 2012; Stura et al., 2013; Van Doren, 2015; Prior et al., 2016) . In this case it seems that the MMP hemopexin and catalytic domains contribute to shifting the equilibrium state of the cleavage-site region toward a locally unfolded triple helix. It is likely that a similar scenario occurs with the procollagen system, where PCPE-1 plays the role of the hemopexin domain. But the procollagen system is even more complex as BTPs themselves include a number of non-catalytic CUB and EGF domains involved in substrate recognition and PCPE-1 activity (Hartigan et al., 2003) . The precise roles of these domains remain to be elucidated.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Culture Human (female) FreeStyle TM HEK293-F cells (Thermo Fisher Scientific) were grown in FreeStyle TM 293 Expression Medium at 37 C with 8% CO 2 .
METHOD DETAILS Protein Expression and Purification
All coding sequences were obtained by PCR amplification from cDNAs. CPIII-His and CPIII-Long with N-terminal fused His-tags cloned into the pHLsec vector have been described (Bourhis et al., 2012b (Bourhis et al., , 2013 . Their numbering starts at the P1 0 position in the BTP cleavage site ( Figure 1A ) with negative numbers used on the N-terminal side. The C1C2 fragment of PCPE-1 spans residues 1 to 252 of the mature protein (i.e. after removal of the 25-residue signal sequence, UniProt Q15113). For structural studies, C1C2 with a C-terminal fused His-tag cloned into the pHLsec vector was used (Bourhis et al., 2013) . For the preparation of C1C2 mutants (and wild-type control), cDNA coding for C1C2 was first cloned into a modified pCEP-Pu vector (Kohfeldt et al., 1997) . In the secreted protein, a vector-derived APLA sequence is present at the N-terminus, and a fused His-tag (AAAHHHHHH) is present at the C-terminus. The C1C2 point mutations were introduced using QuikChange II XL (Agilent Technologies).
Proteins were expressed using the FreeStyle TM 293 Expression System (Thermo Fisher Scientific) following the manufacturer's protocols. Briefly, 293F cells were grown in a shaking incubator at 37 C with 8% CO 2 in serum-free 293 Expression Medium to a cell density of 10 6 cells/ml. Transfections were performed using linear polyethylenimine (PEI; MW 25,000; Polysciences) and a
